Dmg interactions

Elucidation of the stmctural requirements for dmg interaction at the recognition site is by the study of stmcture—activity relationships (SAR), in which, according to a specific biologic response, the effects of systematic molecular modification of a parent dmg stmcture are determined. Such studies have permitted the classification of discrete classes of pharmacological receptors. For example, the neurotransmitter acetylcholine acts at both peripheral and central receptors which are of at least three distinct types. The effects of acetylcholine are mimicked in smooth and cardiac muscles and secretory... 

In the case of dmg interactions involving metabolic inhibition, little increase in the substrate concentration is expected when the inhibition constant (K ) determined in in vitro studies using human liver samples is larger than the inhibitor concentration in vivo. Various approaches have been adopted using mathematical models in attempts to quantitatively predict in vivo dmg interactions from in vitro data [5]. 

Stockley I (1991) Dmg interactions, 2nd edn. Blackwell Scientific Publications, Oxford. 

Washington, U. O. (2003) Dmg Interaction Database http //depts.washington.edu/ didbase/index. shtml. 

Editor s note In the field of dmg interactions there is a mass of unsupported and unsupportable information , particularly in the area of herbals. We therefore want to refer the reader first of all to Stockley s Dmg Interactions (see Baxter K, 2007). By listing the latter in the bibliography the reader is provided with somewhere to go where the original documentation can be found. 

Fuhr U. Dmg interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998 18(4) 251-72. 

Dmg interactions Drug interactions between Neupogen and other drugs have not been fully evaluated. Drugs that may potentiate the release of neutrophils from bone marrow, such as lithium, should be used with caution. 

Barone GW, Gurley BJ, Kotel BL, Abul-Ezz SR. Herbal supplements a potential for dmg interactions in transplant recipients. Transplantation 2001 71 239-241. 

Despite these complexities, all is not lost. Through careful planning and subsequent analysis of both in vitro and in vivo data, progress is being made in our understanding of the mechanisms and pharmacokinetic aspects of dmg interactions. 

Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice furocoumarin dimers as components of dmg interaction. Pharmacogenetics 1997 7 391-396. 

Fukuda K, Ohta T, Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A possible involvement of non-flavonoid components in dmg interaction. Biol Pharm Bull 1997 20 560 564. 

Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Dmg interactions of clinical significance. Drug Saf 1998 18 83-97. 

Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings a new type of dmg/dmg interaction. Clin Pharmacol Ther 2000 68 345-355. 

---